Nitric oxide (NO)-donors: the Nicox expertise
Nicox has developed a leading position in the therapeutic application of NO-donating compounds, based on a strong research platform which creates New Molecular Entities (NMEs). Our specialized Research Center in Italy has worked on many R&D studies covering various therapy areas such as cardiovascular, inflammation and ophthalmology creating one of the most significant patent portfolios in the area. Nicox’s compounds, known as NO-donors, are designed to donate nitric oxide with a sustained pharmacological effect at tissue level aiming at avoiding the drawbacks related to the rapid burst of nitric oxide associated with traditional nitrates.
Focus on ocular disorders
Consistent with Nicox’s strategic positioning in ophthalmology our research platform is focused on ocular conditions where nitric oxide (NO) has been shown to play an important role. A specialized team in Nicox’s Italian research center, Nicox Srl, is pursuing targeted projects in collaboration with external research centers. This will enable Nicox to enhance its knowledge of the role and potential of nitric oxide (NO) in ophthalmology and to leverage its long-standing expertise in the therapeutic application of NO-donating compounds. Several studies conducted in animal models, as well as in humans, have shown that the release of NO reduces IOP1,2. The positive Phase 2 and Phase 3 results obtained with latanoprostene bunod and the subsequent approval of VYZULTA by the U.S. FDA validate the potential of our NO-donating proprietary research platform in ophthalmology.